---
run_id: halo-evidence-vs-diagnosis-validation-v10-vanilla-04
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: vanilla
run_number: 4
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 401
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
condition_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
output_file: model-outputs/vanilla-04.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 04)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `vanilla`, run 4 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 401, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the **Claim File Review**.

Your current growth is a "false positive" created by commercial incentives (bundle pricing) and managerial vanity (ops managers using the tool for training/oversight), rather than adjuster utility. The most critical risk to your business is not a lack of sales momentum, but a fundamental failure of the product's core value proposition: adjusters are abandoning the tool because it lacks "explainability," particularly in regulated segments.

The Usage Quality Sprint tracks *that* people are using it, and the Commercial Cleanroom tracks *if* people will pay for it, but only the Claim File Review tells you *why* it is failing at the point of execution. Without knowing if suggestions are being overridden or rewritten, you are scaling a "black box" that adjusters don't trust and cannot defend to reviewers.

### The Strongest Reason Against It
The Claim File Review is a slow, qualitative process that provides no immediate "commercial" signal to the board. While Sales and Product Analytics are offering metrics that look like growth or efficiency, a File Review produces a set of "failures" and "overrides." In a high-momentum quarter, recommending a process that explicitly hunts for product deficiencies can be perceived by the executive team as "momentum-killing" or overly academic compared to the immediate revenue signals of a Commercial Cleanroom.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "abandonment" in the health-liability segment is a minority edge case and that the majority of expansion bookings are coming from buyers who are explicitly citing DraftPath's *current* output as the primary reason for their renewal, regardless of whether front-line adjusters are using it. If the "Buyer" (who signs the check) values the oversight capabilities for managers more than the productivity gains for adjusters, the product is actually a "Managerial Audit Tool," not a "Workflow Tool." In that case, the technical flaws in the adjuster's experience are secondary to the commercial value of the oversight.
